GGrantIndex
Sort

51,593 grants matching hepatitis

Genetic Regulation of Nonalcoholic Fatty Liver Disease

$537,831
Marisa Wong Medina · University Of California, San Francisco · R01 · FY2024 · DK

Epidemiologic Study of Hepatocellular Carcinoma in the US

$537,816
Herbert Yu · Yale University · R01 · FY2011 · CA

Alcohol-induced hepatotoxicity - implications of secretin/secretin receptor axis

$537,781
Gianfranco D. Alpini · Indiana University Indianapolis · R01 · FY2022 · AA

Continuum of Care for Drug-Involved Offenders

$537,760
Peter D. Friedmann · Rhode Island Hospital · U01 · FY2013 · DA

Role of evolving white matter damage in neurocognitive effects of HIV and HCV

$537,753
Terry L Jernigan · University Of California, San Diego · R01 · FY2007 · MH

Metabolic Markers and Predictors of Childhood Obesity

$537,736
Sonia Caprio · Yale University · R01 · FY2015 · HD

A 4D-tunable hydrogel for the study of the impact of the tumor microenvironment on the development of colorectal cancer

$537,714
Nancy L Allbritton · University Of Washington · R01 · FY2025 · CA

STING-Dependent Pathways Restraining Severe Schistosome Immunopathology

$537,712
Parisa Kalantari · Tufts University Boston · R01 · FY2020 · AI

HIV/STD Infection in an Urban High Risk Population

$537,693
Larry Allen Nuttbrock · National Development And Research Institutes, Inc. · R01 · FY2008 · DA

Regulation of Drug Metabolizing Enzyme Ontogeny

$537,671
D Gail McCarver · Medical College Of Wisconsin · R01 · FY2012 · GM

Molecular Mechanisms of Insulin Resistance Associated Loci

$537,659
Thomas None Quertermous · Stanford University · R01 · FY2019 · DK

A single biosensors for the simultaneous molecular detection of HIV and Hepatitis B and C viruses at resource-limited settings

$537,619
Karin Chumbimuni-Torres · University Of Central Florida · R15 · FY2025 · AI

The Development of TGR5 Antagonists for the Treatment of Cholangiopathies

$537,612
Steven H Olson · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2019 · DK

Yale Drug use, Addiction and HIV Research Scholars (DAHRS)

$537,598
Gail D'onofrio · Yale University · K12 · FY2018 · DA

Effect of structural interventions on substance use and HIV/HCV risk among rural PWUD

$537,587
Jennifer R Havens · University Of Kentucky · R01 · FY2019 · DA

Identifying an immunoregulatory axis for FGF21 in alcohol consumption

$537,587
Suraj J Patel · Ut Southwestern Medical Center · R01 · FY2025 · AA

Identifying an immunoregulatory axis for FGF21 in alcohol consumption

$537,587
Suraj J Patel · Ut Southwestern Medical Center · R01 · FY2024 · AA

HBV Capsid Effectors

$537,558
Raymond F. Schinazi · Emory University · R01 · FY2019 · AI

Small molecule allosteric inhibitors of PCSK9 processing to phenocopy cardioprotective genetic variants.

$537,538
John S Chorba · University Of California, San Francisco · R61 · FY2023 · HL

Implementation of Seek, Test, Treat & Retain Strategies among People Who Inject Drugs in Malaysia

$537,496
Marek C Chawarski · Yale University · R01 · FY2019 · DA

Community Wise: An innovative multi-level intervention to reduce alcohol and illegal drug use

$537,492
Liliane Cambraia Windsor · University Of Illinois At Urbana-Champaign · U01 · FY2016 · MD

Spinal cord injury causes liver pathology and metabolic dysfunction

$537,485
Dana M McTigue · Ohio State University · R01 · FY2022 · DK

Spinal cord injury causes liver pathology and metabolic dysfunction

$537,485
Dana M McTigue · Ohio State University · R01 · FY2023 · DK

Spinal cord injury causes liver pathology and metabolic dysfunction

$537,485
Dana M McTigue · Ohio State University · R01 · FY2025 · DK

Action Plans & Memory Consolidation: Reducing HIV Risk in Drug Users

$537,448
Alan W Stacy · Claremont Graduate University · R01 · FY2014 · DA